Hartung Evelyn, Becker Martina, Bachem Annabell, Reeg Nele, Jäkel Anika, Hutloff Andreas, Weber Harald, Weise Christoph, Giesecke Claudia, Henn Volker, Gurka Stephanie, Anastassiadis Konstantinos, Mages Hans W, Kroczek Richard A
Molecular Immunology, Robert Koch-Institute, 13353 Berlin, Germany;
Institute of Chemistry and Biochemistry, Free University, 14195 Berlin, Germany;
J Immunol. 2015 Feb 1;194(3):1069-79. doi: 10.4049/jimmunol.1401903. Epub 2014 Dec 17.
Current subunit vaccines are incapable of inducing Ag-specific CD8(+) T cell cytotoxicity needed for the defense of certain infections and for therapy of neoplastic diseases. In experimental vaccines, cytotoxic responses can be elicited by targeting of Ag into cross-presenting dendritic cells (DC), but almost all available systems use target molecules also expressed on other cells and thus lack the desired specificity. In the present work, we induced CD8(+) T cell cytotoxicity by targeting of Ag to XCR1, a chemokine receptor exclusively expressed on murine and human cross-presenting DC. Targeting of Ag with a mAb or the chemokine ligand XCL1 was highly specific, as determined with XCR1-deficient mice. When applied together with an adjuvant, both vector systems induced a potent cytotoxic response preventing the outgrowth of an inoculated aggressive tumor. By generating a transgenic mouse only expressing the human XCR1 on its cross-presenting DC, we could demonstrate that targeting of Ag using human XCL1 as vector is fully effective in vivo. The specificity and efficiency of XCR1-mediated Ag targeting to cross-presenting DC, combined with its lack of adverse effects, make this system a prime candidate for the development of therapeutic cytotoxic vaccines in humans.
目前的亚单位疫苗无法诱导针对某些感染的防御和肿瘤疾病治疗所需的抗原特异性CD8(+) T细胞细胞毒性。在实验性疫苗中,通过将抗原靶向交叉呈递树突状细胞(DC)可引发细胞毒性反应,但几乎所有现有系统使用的靶分子也在其他细胞上表达,因此缺乏所需的特异性。在本研究中,我们通过将抗原靶向XCR1(一种仅在小鼠和人类交叉呈递DC上表达的趋化因子受体)来诱导CD8(+) T细胞细胞毒性。用单克隆抗体或趋化因子配体XCL1靶向抗原具有高度特异性,这在XCR1缺陷小鼠中得到证实。当与佐剂一起应用时,两种载体系统均诱导了有效的细胞毒性反应,阻止了接种的侵袭性肿瘤的生长。通过生成仅在其交叉呈递DC上表达人XCR1的转基因小鼠,我们可以证明使用人XCL1作为载体靶向抗原在体内是完全有效的。XCR1介导的抗原靶向交叉呈递DC的特异性和效率,以及其缺乏不良反应,使其成为开发人类治疗性细胞毒性疫苗的主要候选者。